|
|
||||||||



* Laboratory of Bacteriology and Medical Micology, Istituto Superiore di Sanità, Rome, Italy;
Laboratory of Immunology and Unesco Center, Istituto Nazionale Malattie Infettive "L. Spallanzani" Hospital, Rome, Italy; and
Section of Toxicology and Biomedicine, Ente Nazionale Energie Alternative, Casaccia, Rome, Italy
| Abstract |
|---|
|
|
|---|
B
activation by anti-CD3/CD28 stimulation. These findings demonstrate
that at least two novel signal pathways regulate CTLA-4 gene expression
and CD152 molecule up-regulation in human CD4+ T
lymphocytes, in the absence of full T cell
activation. | Introduction |
|---|
|
|
|---|
The role of cAMP as a second messenger in cells of the immune system has been widely described (8). In particular, elevation of intracellular cAMP in T lymphocytes has an inhibitory effect on proliferation and IL-2 production (9), and has been shown to affect early T cell activation events (10). In this study, we have investigated whether there is any relationship between the increase of intracellular cAMP and CD152 expression in human CD4+ T lymphocytes.
cAMP binds to and activates protein kinase A (PKA),2 which in turn phosphorylates downstream effector proteins such as Csk or transcription factors that bind to a cAMP-responsive element in the DNA, named CREB (11). However, alternative pathways of cAMP action independent from PKA have been described (12). It is known that cAMP is able to open cation channels permeable to Ca2+, and the level of Ca2+ in turn can regulate cAMP levels by activating or inhibiting either adenylyl cyclases or phosphodiesterases (13). However, the molecular interplay between Ca2+ and cAMP signaling in T lymphocytes is not completely defined. In this study, we show that cAMP induces CD152 expression on resting CD4+ T lymphocytes and that the combination of cAMP and the Ca2+ ionophore ionomycin (Ion) further enhances the expression of CD152 in these cells.
| Materials and Methods |
|---|
|
|
|---|
RPMI 1640 supplemented with 2 mM L-glutamine, 1% nonessential amino acids, 1% pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin (Life Technologies, Grand Island, NY), and 10% FCS (HyClone Laboratories, Logan, UT) was used as complete medium in all cultures. Anti-CD3 (clone UCHT1) and anti-CD28 (clone CD28.2) mAbs were purchased from Immunotech (Westbrook, ME) and BD PharMingen (San Diego, CA), respectively. Cholera toxin (CT) and CT B subunit (CT-B) were purchased from Calbiochem-Novabiochem (San Diego, CA); forskolin (FSK), dibutyryl cAMP (dbcAMP), Ion, and cyclosporin A (CsA) were purchased from Sigma-Aldrich (St. Louis, MO).
Lymphocyte purification and cell cultures
PBMC were isolated from healthy donors by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density centrifugation. CD4+ T lymphocytes were purified by negative selection using an immunomagnetic cell sorting (Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, PBMC were labeled using a cocktail of hapten-conjugated mAbs anti-CD8, CD11b, CD16, CD19, CD36, and CD56 molecules and MACS MicroBeads coupled to an anti-hapten mAb. The magnetically labeled cells were depleted by retaining them on a column using MidiMACS cell separator. PBMC or CD4+ purified T cells (2 x 106/ml) were treated either with CT (3 µg/ml), CT-B (3 µg/ml), dbcAMP (from 0.01 to 0.5 mM), FSK (50 µM), or Ion (200 ng/ml), and analyzed at different time points. PBMC were also stimulated with anti-CD3 mAb (1 µg/ml). In some experiments, CsA (1 µg/ml) was used as inhibitor of Ca2+/calcineurin signal pathway.
Flow cytometry analysis
FITC- or PE-conjugated anti-CD4, CD152, CD25, and CD69 mAbs and their isotype-matched controls were purchased from BD PharMingen (San Diego, CA) and used for direct immunofluorescence staining. CD152 detection was performed by intracellular staining. Briefly, cells were washed twice in PBS, 1% BSA, and 0.1% sodium azide and stained with anti-CD4 mAb on the membrane for 15 min at 4°C. Samples were then fixed in 4% paraformaldehyde for 5 min at 4°C; incubated with anti-CD152 mAb; and diluted in PBS, 1% BSA, and 0.5% saponin. The cells were finally washed twice in PBS, 1% BSA, and 0.1% saponin, and acquired on a FACSCalibur instrument running CellQuest software.
CD152 mRNA analysis by RT-PCR
Total RNA was extracted using RNAFast reagent (Life
Technologies), according to the manufacturers recommendations. The
single-stranded cDNA was synthesized using 1 µg of RNA by reverse
transcription using random examers (Invitrogen, San Diego, CA). PCR
were performed with cDNA corresponding to 10 ng of RNA, Taq
polymerase (Invitrogen), and primers designed to amplify the entire
coding sequence of CD152: 5'-ATGGCTTGCCTTGGATTTCAGCGGCACAAGG-3' and
5'-TCAATTGATGGGAATAAAATAAGGCTGAAATTGC-3'. PCR was as follows:
94°C for 5 min, 30 cycles 94°C for 30 s, 58°C for 30 s,
and 72°C for 30 s, followed by a final extension at 72°C for 7
min. The amplified fragments were separated on 1% agarose gel and
visualized by ethidium bromide. RNA integrity and cDNA synthesis were
verified by amplifying
2-microglobulin cDNA.
The intensity of the revealed bands was directly quantified by Image
QuaNT software (Amersham Pharmacia Biotech, Piscataway, NJ),
which gives rise to a volume report (expressed as arbitrary units,
a.u.) by integrating the area of the bands and their OD. CD152 mRNA
values were normalized to those of
2-microglobulin and expressed as a.u.
Electrophoretic mobility shift assay
Binding reactions containing 12 µg cell extracts, 10 mM
Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM DTT, 1 mM PMSF, 0.5 mM EDTA, 10%
glycerol, 0.5 mg poly(dI-dC), and 1 µg BSA were incubated for 30 min
with 5000 cpm of 32P-end-labeled double-stranded
oligonucleotide in a total volume of 10 ml. The probe was
5'-AGTTGAGGGGACTTTCCCAGGC-3'. Labeling of the probe was obtained by
incubating 10 pmol of oligonucleotide with 10 pmol
[
-32P]ATP and 10 U T4 polynucleotide kinase
for 30 min at 37°C. The probe was then purified with Micro BIO-Spin
P-30 columns. Complexes were separated on 6% polyacrylamide gel. After
drying, gels were exposed on phosphor screen and were then analyzed by
phospho/fluorescence imager STORM 840 (Amersham Pharmacia Biotech). The
intensity of the revealed bands was directly quantified by Image QuaNT
software (Amersham Pharmacia Biotech).
| Results |
|---|
|
|
|---|
To investigate whether intracellular increase of cAMP had any
effects on the expression of CD152, we treated human PBMC with an
analog of cAMP, dbcAMP, or with agents that increase intracellular cAMP
and analyzed CD152 expression in CD4+ T
lymphocytes by intracellular staining (Fig. 1
). An increase in the percentage of
CD4+CD152+ cells was
evident already after 3 h of incubation with dbcAMP and, after
24 h, 45% of the CD4+ T cells were
CD152+ (Fig. 1
A). The up-regulation of
CD152 by dbcAMP was dose dependent, as shown in Fig. 1
B. The
increase of CD152 expression was also observed with FSK, which directly
activates adenylyl cyclase, and with CT, a bacterial toxin that causes
intracellular cAMP increase by ADP ribosylation of Gs proteins (Fig. 1
A). In contrast, treatment with CT-B, the B subunit of CT,
which lacks the ADP-ribosyl transferase activity, did not affect the
up-regulation of CD152. Finally, anti-CD3 mAb-activated cells,
which were included in the experiments as a positive control, showed a
high CD152 up-regulation, as expected (Fig. 1
, A and
B).
|
To evaluate whether cAMP-dependent up-regulation of CD152 correlated
with an increase of mRNA, we analyzed the CD152 mRNA in PBMC cultured
in the presence of dbcAMP (Fig. 2
). We
observed an increase of two mRNA transcripts that correspond to the
membrane (672-bp) and the soluble (550-bp) molecule of CD152
(14). Altogether, these results show that the increase of
intracellular cAMP leads to increased CD152 mRNA and protein levels in
T lymphocytes, and that this occurs in the absence of full T cell
activation.
|
To investigate whether the effect of cAMP on CD152 expression was
affected by increased Ca2+ levels in T cells,
purified CD4+ T lymphocytes were treated with Ion
in the presence or absence of dbcAMP or cAMP inducers. We found that
Ion alone up-regulated CD152 to a similar degree as dbcAMP, FSK, or CT
(Fig. 3
A). However, a stronger
induction of CD152 was observed by concomitant treatment of the cells
with Ion and either dbcAMP, FSK, or CT, with >70% of the
CD4+ T cells expressing CD152 after 24 h of
culture (Fig. 3
A). The expression level of CD152 relative to
the single cell, expressed as mean fluorescence intensity (MFI), was 14
in the absence of any stimuli and increased to 3038 with the
different stimuli (Fig. 3
B). However, an increase of the MFI
value to 175261 was observed after concomitant treatment with Ion and
dbcAMP, FSK, or CT (Fig. 3
B). These data show that the
effects of cAMP and Ca2+ on purified
CD4+ T cells are more than additive, suggesting
an active integration of the two signaling pathways. At the mRNA level,
a stronger up-regulation of the transcripts corresponding to the
membrane and the soluble CD152 molecule was observed with the
combination of dbcAMP and Ion as compared with the single treatments
(Fig. 2
). Finally, the up-regulation of CD152 mediated by Ion alone or
by the combination of Ion and the cAMP inducers occurred in the absence
of proliferation and expression of the activation markers CD25 and CD69
(data not shown).
|
It has been described that cAMP can influence
Ca2+ levels in different cell types, and that
many adenylyl cyclase isoforms are Ca2+
dependent. In the attempt to understand the relationship between
Ca2+ and cAMP signaling pathways in the
up-regulation of CD152, purified CD4+ T cells
were treated with CsA, which is known to interfere with the
Ca2+/calcineurin signaling pathway. CsA fully
prevented the Ion-induced up-regulation of CD152 (Fig. 4
A), confirming that
Ca2+-mediated signals are involved in CD152
up-regulation. However, CsA did not affect the induction of CD152
mediated by dbcAMP or FSK (Fig. 4
B), and only partially
prevented the up-regulation of CD152 in the presence of both Ion and
dbcAMP or Ion and FSK (Fig. 4
C). These data suggest that the
up-regulation of CD152 mediated by cAMP is independent from
Ca2+ signals, and that at least two signaling
pathways may regulate CD152 expression in T lymphocytes.
|
To verify whether CD152 up-regulation induced by cAMP and Ion
results in inhibitory effects on T cells, purified
CD4+ T cells were cultured with anti-CD3,
anti-CD28, and anti-CD152 mAbs in the presence or absence of
CT, Ion, or both. Cell extracts were probed with a radiolabeled NF-
B
consensus sequence and resolved by EMSA. The data in Fig. 5
show that CT and Ion alone induced
NF-
B activation and that their combination resulted in a slightly
higher stimulation. Furthermore, the engagement of membrane CD152 by
mAbs in CT- or Ion-treated cells inhibited NF-
B activation by 48 and
33%, respectively, and in cells treated with both CT and Ion
inhibition of NF-
B activation was 54%. Altogether, these results
show that CD152 molecules that have been up-regulated by cAMP and Ion
either alone or in combination are expressed on the cell membrane, and
that their engagement by anti-CD152 mAb results in inhibitory
effects in T lymphocytes.
|
| Discussion |
|---|
|
|
|---|
In addition to cAMP, we found that Ion induces up-regulation of CD152 in resting CD4+ T cells, suggesting that a Ca2+-dependent signal transduction pathway is involved in CD152 up-regulation in human T lymphocytes. We also observed a synergistic effect of increased cAMP and Ca2+ levels on the up-regulation of CD152 expression; however, the molecular interplay between cAMP and Ca2+ is not completely defined.
cAMP and Ca2+ are important second messengers responsible for the regulation of many cellular events. The stimulation of different membrane receptors by hormones, neurotransmitters, or mitogens leads to increased levels of cytosolic Ca2+ and to the regulation of many physiological functions of T lymphocytes, including proliferation and cytokine production (16). Endogenous molecules such as catecholamines, PGE2, and histamine also modulate intracellular levels of cAMP; however, the rise of intracellular cAMP generally leads to the inhibition of T cell function. The understanding of how the signaling pathways mediated by cAMP and Ca2+ are integrated in the cells has been the objective of many studies. It has been reported that different isoforms of adenylyl cyclase are regulated by intracellular Ca2+ levels (17). In contrast, cAMP is known to regulate Ca2+ levels both directly by opening cation channels and indirectly through PKA (18). In this study, we observed that CsA prevented the up-regulation of CD152 induced by Ion, but not that induced by dbcAMP, CT, or FSK, suggesting that cAMP up-regulates CD152 through a Ca2+-independent pathway. Thus, our results show that two novel signaling pathways regulate CD152 expression.
We observed increased CD152 mRNA in cells treated with dbcAMP, Ion, or both. Two mRNA variants coding for membrane and soluble CD152 molecules are known to be expressed in resting T lymphocytes; however, the mRNA for the soluble form is found only in nonactivated cells and is inhibited upon T cell activation (14). Interestingly, the up-regulation of human CD152 by cAMP and Ca2+ in resting T lymphocytes involves both isoforms of mRNA transcripts. The increase of CD152 expression by cAMP and Ca2+ could be regulated at the transcriptional level or due to changes in CD152 mRNA stability.
CD152 molecules localize primarily to intracellular compartments, and
their expression on the T cell surface, at immunological synapses, is
proportional to the intensity of the TCR signal (19). In
this study, we found that CD152 molecules up-regulated by cAMP in
resting T cells localize on the cell surface and mediate functional
effects, because anti-CD152 mAbs inhibited the activation of
NF-
B. The inhibition of this transcription factor is relevant for
the control exerted by CD152 on cytokine production (20).
In addition, we found that CT by itself activates NF-
B. This effect
may be due to its B subunit, as it has been described for the
homologous Escherichia coli heat-labile enterotoxin
(21).
Increased intracellular cAMP has been implicated in the induction of T cell anergy (22), a state of unresponsiveness, which occurs when T cells are stimulated through CD3/TCR in the absence of costimulation. It has also been reported that CD152 plays an important role in the induction of anergy (23). In this regard, we have previously shown that CD152 ligation by CD80 is required for the induction of unresponsiveness of CD4+ T cells, in a costimulation-deficient Ag presentation system (24). In addition, CD152 has been shown to be involved in the maintenance of peripheral tolerance, because T cell tolerance was abrogated in CD152-deficient TCR transgenic mice (5) and by blocking CD152 engagement in vivo (25). Furthermore, CD4+CD25+ regulatory T cells, which display an anergic phenotype and exert immunosuppressive functions, constitutively express CD152 (26, 27), although further studies are needed to elucidate the role of CD152 in these cells.
A physiological role of cAMP- and Ca2+-induced up-regulation of CD152 on T cells could be the modulation of the inflammatory reaction. Indeed, metabolites that act through cAMP pathways, such as adenosine, are released in inflamed tissues (28). We are currently investigating the function of T lymphocytes treated with cAMP.
In conclusion, we demonstrated that CD152 expression is up-regulated by cAMP and Ca2+ influx in resting T lymphocytes. This suggests that CD152, which is normally involved in the termination of immune responses, may also play an important role in preventing T cell activation. The up-regulation of mRNA for the soluble CD152 form suggests that the inhibitory effects may be further amplified. Thus, substances that increase intracellular cAMP could be a tool for the generation of resting CD4+CD152+ T cells that may be useful for therapeutic purposes, such as the treatment of autoimmune and inflammatory diseases or the prevention of transplanted organ rejection.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Abbreviations used in this paper: PKA, protein kinase A; a.u., arbitrary unit; CsA, cyclosporin A; CT, cholera toxin; CT-B, CT B subunit; dbcAMP, dibutyryl cAMP; FSK, forskolin; Ion, ionomycin; MFI, mean fluorescence intensity. ![]()
Received for publication August 1, 2002. Accepted for publication October 4, 2002.
| References |
|---|
|
|
|---|
B
degradation and RelA activation. Eur. J. Immunol. 29:856.[Medline]
This article has been cited by other articles:
![]() |
J. Bodor, Z. Fehervari, B. Diamond, and S. Sakaguchi Regulatory T cell-mediated suppression: potential role of ICER J. Leukoc. Biol., January 1, 2007; 81(1): 161 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Vendetti, M. Patrizio, A. Riccomi, and M. T. De Magistris Human CD4+ T lymphocytes with increased intracellular cAMP levels exert regulatory functions by releasing extracellular cAMP J. Leukoc. Biol., October 1, 2006; 80(4): 880 - 888. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Zheng, J. H. Wang, W. Stohl, K. S. Kim, J. D. Gray, and D. A. Horwitz TGF-beta Requires CTLA-4 Early after T Cell Activation to Induce FoxP3 and Generate Adaptive CD4+CD25+ Regulatory Cells J. Immunol., March 15, 2006; 176(6): 3321 - 3329. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Stohl, D. Xu, K. S. Kim, C. S. David, and J. P. Allison MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4) Int. Immunol., July 1, 2004; 16(7): 895 - 904. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |